Abbott Shares Drop 8% After Q4 Revenue Miss; Nutrition Sales Slide
Abbott Laboratories (ABT) shares tumbled about 8% on Friday after the company reported Q4 revenue of $11.5 billion, below the $11.8 billion consensus. The shortfall was driven largely by an 8.9% drop in nutrition sales, which management attributed to pricing pushback from customers and elevated input costs. The miss surprised investors given nutrition’s role as a steady cash generator and prompted a sharp intraday sell-off.
The result raises near-term concerns over margin pressure and could influence Abbott’s tone on forward guidance when management provides updates. Analysts and investors will be watching for any comments on pricing strategy, cost mitigation, and timing for a recovery in the nutrition business. The pullback in ABT may also weigh on healthcare peers and defensive sectors, making upcoming earnings calls and guidance revisions key for positioning.